Conmed (CNMD) Tops Q1 EPS by 9c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
CONMED (CNMD) PT Raised to $73 at Needham & Company
April 26, 2018 6:54 AM EDTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $73.00 (from $71.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "CNMD's 1Q18 revenue and EPS beat consensus and management raised its 2018 revenue and EPS guidance. Revenue growth slowed somewhat to 6.8% CC... More
